002287:SZSETibet Cheezheng Tibetan Medicine Co., Ltd. Analysis

Tibet Cheezheng trades at CNY 21.97, which is well above its DCF‑derived fair value of roughly CNY 8.3, signaling a material overvaluation despite a trailing P/E of 18 that is lower than the industry average of 29. The company enjoys robust profitability – gross margin of 83% and operating margin of 22% – but revenue growth is flat at 0.6%, limiting upside potential. Technical signals are mixed: price sits near the resistance level of CNY 22.13, the 20‑day SMA (20.0) is below the 50‑day SMA (20.8), and the trend is flagged as bearish, yet the MACD histogram is positive and the RSI at 65 hints at short‑term overbought conditions. Volatility is high at 33.7% over the past 30 days, while beta is slightly negative, suggesting limited correlation with the broader market. The dividend yield of 4.71% with a payout ratio under 50% appears sustainable given solid operating cash flow, though free cash flow is negative.
Overall, the stock offers attractive income but faces limited growth, a pronounced valuation gap, and elevated market risk, implying that investors should be cautious and prioritize income stability over price appreciation.